Agreed. Covidien must be looking at potential for international sales if we're going to make a robot. The US market will be past the point of saturation by the time it comes out, and it's likely that lack of improved clinical outcomes and reimbursement for robotics will have reshaped market demand. I guess somebody has to step up and take on ISI, but unless it's a crazy good next generation platform, I don't see much success in the US.